FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Evaluating the Influence of a Risk Calculator on Physician Risk Perception and Decision-Making in IPMN Surveillance: A Randomized Trial. PMID 41649782 · Ann Surg Oncol · 2026-May The study is a randomized trial in human oncology (pancreatic IPMN), but it is not eligible because it does not involve a drug-containing intervention, and its primary endpoints are clinician risk perception and decision-making, not a patient time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Time to Follow-Up Colonoscopy After Positive Fecal Immunochemical Test with Centralized Patient Navigation: A Randomized Clinical Trial. PMID 41639370 · J Gen Intern Med · 2026-May The study is a randomized clinical trial in an oncology setting (colorectal cancer screening) with a time-to-event endpoint (time to colonoscopy). However, it fails multiple key inclusion criteria: it is not a Phase III/IIIb or Phase II/III trial, the intervention is non-drug (patient navigation), and the endpoint is a diagnostic process measure, not a treatment efficacy endpoint (OS, PFS, etc.). Therefore, it is not eligible for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients. PMID 41633900 · Eur Urol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Celecoxib Combined With Low-Dose-Rate Brachytherapy on Long-Term Oncological Outcomes and Quality of Life in Prostate Cancer: Post Hoc Analysis of an Open-Label Controlled Randomized Trial. PMID 41570179 · Prostate · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comment on: ALBAN (GETUG-AFU 37): a phase III, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). PMID 41539604 · Ann Oncol · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials. PMID 41534788 · J Thorac Oncol · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Romiplostim in Treating Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatric Patients: A Single-Arm Clinical Trial. PMID 41500465 · Transplant Cell Ther · 2026-May The study is a single-arm, non-randomized trial, which excludes it from eligibility for a randomized controlled trial cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| In-Office Laser Coagulation of Ta Bladder Tumor Compared With Transurethral Resection of Bladder Tumor: 12 Months Follow-Up Randomized Clinical Trial. PMID 41461083 · J Urol · 2026-May The study is a randomized, non-inferiority trial comparing two non-drug interventions (laser coagulation vs. TUR-BT) for low-grade bladder cancer. It is excluded because it does not meet the required 'drug-containing intervention' criterion. The phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided record, but the primary exclusion is the lack of a drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial. PMID 41443411 · Ann Oncol · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in the treatment of Bowen's disease: Long-term results of a multicenter randomized controlled trial. PMID 41391634 · J Am Acad Dermatol · 2026-May The study is a randomized, multicenter trial with a primary time-to-event endpoint (tumor-free survival) and includes a drug intervention (5-fluorouracil). However, it is not explicitly identified as a Phase III or definitive trial, and the condition (Bowen's disease) is a non-metastatic skin lesion, making it a borderline oncology context. The primary endpoint, while time-to-event, is not a standard oncologic efficacy endpoint like OS, PFS, or DFS for advanced disease. The deterministic review correctly flagged the lack of clear phase and standard time-to-event signal. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study. PMID 41381401 · J Gynecol Oncol · 2026-May 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequential analysis of randomized controlled trials. PMID 41381268 · Surgery · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A randomized study comparing outcomes of intravesical Gemcitabine, Mitomycin C (as hyperthermic intravesical chemotherapy-HIVEC) and Bacillus-Calmette Guerin in intermediate and high-risk non-muscle invasive bladder cancer. PMID 41216726 · Urologia · 2026-May Eligibility cannot be confirmed because the trial phase (Phase III/IIIb or Phase II/III) is not explicitly established in the provided record. While the study is an original randomized trial with a time-to-event endpoint and drug intervention, the 'preliminary findings' and 'limited sample size' noted in the conclusion, combined with the lack of a clear phase designation, prevent definitive inclusion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Endoscopic ultrasound-guided transpapillary versus transluminal biliary stenting: randomized comparison of long-term stent patency. PMID 41077045 · Endoscopy · 2026-May 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| The Effect of Cognitive Behavioral Therapy-Based Psychoeducation on Anger Management and Death Anxiety in Individuals Receiving Chemotherapy: A Randomized Controlled Trial. PMID 38517134 · Omega (Westport) · 2026-May The study is a randomized trial in oncology patients, but it evaluates a psychoeducational intervention (CBT-based), not a drug. It also does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The phase is not specified as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial. PMID 41916997 · Nat Commun · 2026-Mar-31 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Perineal versus retropubic radical prostatectomy in localized prostate cancer: extended analysis of a prospective randomized cohort. PMID 41914230 · Arch Ital Urol Androl · 2026-Mar-31 The study is an oncology, human, randomized, original result report with a time-to-event endpoint (BCRFS). However, it does not involve a drug-containing intervention (it compares surgical techniques) and the phase of the trial is not specified as Phase III/IIIb or Phase II/III. Therefore, it is excluded based on the lack of a drug intervention and definitive phase evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape. PMID 41930282 · Ann Neurosci · 2026-Mar-30 The record is a systematic review of the clinical trial landscape for metformin repurposing in neurological disorders, not an original report of a randomized trial in oncology. It does not contain results from a specific Phase III/IIIb or Phase II/III trial with a drug-containing intervention and a time-to-event efficacy endpoint. Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Temporary interruption versus maintenance of anticoagulation in polypectomy of colorectal lesions: study protocol for a multicentre randomised non-inferiority clinical trial POLYPHEM. PMID 41916623 · BMJ Open · 2026-Mar-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Baricitinib in moderate to severe rheumatoid arthritis: dose-dependent efficacy and safety in a randomized clinical trial in a developing country. PMID 41913302 · BMC Rheumatol · 2026-Mar-30 The study is a randomized, drug-intervention trial with original results, but it is not an oncology study; it is for rheumatoid arthritis. Therefore, it does not meet the oncology requirement for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Results of the AiM, PLan, and act on LIFestYles (AMPLIFY) Weight Loss Intervention Among Survivors of Obesity-Related Cancers: A Randomized Clinical Trial. PMID 41911893 · J Natl Compr Canc Netw · 2026-Mar-30 The study is a randomized trial in cancer survivors but fails two key eligibility criteria: (1) it evaluates a lifestyle/diet intervention, not a drug-containing intervention, and (2) its primary efficacy endpoint is weight loss (a continuous measure), not a time-to-event endpoint (like OS, PFS, DFS) analyzed via Kaplan-Meier or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Motor Imagery and Action Observation in Breast Cancer Survivors: Protocol for a Randomized Controlled Trial. PMID 41911468 · JMIR Res Protoc · 2026-Mar-30 This is a protocol for a randomized controlled trial evaluating a non-drug rehabilitation intervention (motor imagery/action observation) in breast cancer survivors. It lacks a drug intervention, a time-to-event endpoint, and any trial results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| OPERA: a phase II study of DHP107 (oral paclitaxel) versus intravenous paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer. PMID 41910867 · Breast Cancer Res Treat · 2026-Mar-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of concurrent chemotherapy dose on long-term survival in locally advanced nasopharyngeal carcinoma: a 10-year single-center study. PMID 41904463 · BMC Cancer · 2026-Mar-28 The record does not explicitly establish that this is a Phase III, Phase IIIb, or Phase II/III trial. All other eligibility criteria (oncology, human, randomized, time-to-event endpoint, drug intervention, original result) are met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Zanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial. PMID 41904192 · Nat Commun · 2026-Mar-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Global landscape of yttrium-90 clinical trials: a systematic registry-based analysis. PMID 41896975 · Trials · 2026-Mar-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Interactive symptom monitoring and coaching to optimise toxicity management of chemo(immune)therapy in early stage breast cancer: study protocol of the multicentre randomised controlled eChemoCoach trial. PMID 41888754 · BMC Cancer · 2026-Mar-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Peripheral monocyte ratio as a predictive biomarker for metastasis-directed therapy in prostate cancer: insights from an exploratory study. PMID 41888707 · BMC Cancer · 2026-Mar-26 The record describes a randomized study of an exploratory biomarker (monocyte ratio) for predicting response to metastasis-directed therapy (SBRT) in prostate cancer. It is an oncology human randomized trial with original results, but it does not meet key eligibility criteria: 1) The intervention is not drug-containing (compares iADT alone vs. iADT+SBRT, where SBRT is radiation, not a drug); 2) The endpoint is biochemical response/progression, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc.; 3) It is a subgroup/biomarker analysis, not a primary report of a Phase III/IIIb or II/III drug trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Gemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study. PMID 41888696 · BMC Cancer · 2026-Mar-26 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Prospective randomised trial comparing thermal ablation With laparoscopic Adrenalectomy as an alternatiVE treatment for unilateral asymmetric primary aldosteronism: a protocol for the WAVE trial. PMID 41887640 · BMJ Open · 2026-Mar-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Associations between perceived neighborhood environment and physical activity among breast cancer patients engaged in a physical activity program concomitant to cancer treatment: cross-sectional and longitudinal analyses in the DISCO trial (DiscoSpace). PMID 41882725 · Int J Behav Nutr Phys Act · 2026-Mar-26 The report is an original result of a human Phase III RCT in oncology, but it is a secondary observational analysis (nested within a trial) with a non-drug intervention (physical activity) and non-time-to-event endpoints (physical activity, walking distance). It does not meet the criteria for inclusion as a primary or key secondary efficacy analysis with a time-to-event endpoint and a drug intervention. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Protocol of the LEONORA randomized clinical trial: Lower gastrointestinal symptom burden by prophylaxis with synbiotics after colorectal cancer surgery. PMID 41882573 · BMC Cancer · 2026-Mar-25 This is a protocol for a randomized trial in colorectal cancer patients with a synbiotic intervention. It meets criteria for oncology, human, randomized, and drug intervention. However, it is excluded because it is a protocol without results, not explicitly a Phase III trial, and lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as the primary endpoint is quality of life. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of Anemia on Clinical Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis Receiving Edoxaban - Insights From the ONCO DVT Study. PMID 39293971 · Circ J · 2026-Mar-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Home Treatment for Active Cancer Patients With Low-Risk Pulmonary Embolism - A Predetermined Companion Report From the ONCO PE Trial. PMID 38462535 · Circ J · 2026-Mar-25 This is a randomized trial in cancer patients with pulmonary embolism, but it compares home vs. in-hospital treatment for rivaroxaban use. The primary endpoint is a composite of clinical events (PE-related death, recurrent VTE, major bleeding) at 3 months, reported as proportions, not as a time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier analysis or hazard ratio. It does not meet the criteria for a definitive oncology efficacy trial with a time-to-event endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Longitudinal Analysis of Peripheral Blood CD4+ T-Cell Profiles and Clinical Outcomes in Metastatic Non-Small-Cell Lung Cancer Patients Following Bronchoscopic Cryotherapy and Pembrolizumab-Based Therapy. PMID 41977120 · Int J Mol Sci · 2026-Mar-24 The study is a randomized oncology trial with time-to-event endpoints (PFS, OS) and a drug intervention (pembrolizumab). However, the trial phase is not explicitly stated in the provided metadata (e.g., 'Phase III'). The primary objective appears to be immunologic (T-cell profiles) and radiologic response, with survival as secondary endpoints, and the results show no statistical difference in PFS/OS, making it not definitively a Phase III efficacy trial as required. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A Culturally Tailored Mobile Health Intervention to Improve Quality of Life in Black Survivors With Prostate Cancer: Protocol for a Stratified Randomized Controlled Trial. PMID 41875429 · JMIR Res Protoc · 2026-Mar-24 This is a protocol for a randomized controlled trial, not a final results report. The intervention is a mobile health app (non-drug) and standard care. The primary endpoint is quality of life (not a time-to-event endpoint). It lacks explicit phase information, but the description suggests an early-stage intervention trial, not a definitive Phase III study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial. PMID 41564431 · Blood Adv · 2026-Mar-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Antibiotic Therapy for Uncomplicated Acute Appendicitis: Ten-Year Follow-Up of the APPAC Randomized Clinical Trial. PMID 41563747 · JAMA · 2026-Mar-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of Survey Item Wording and Response Options on Prevalence of Beliefs About Nicotine Causing Cancer: A Randomized Survey Experiment. PMID 41405956 · Nicotine Tob Res · 2026-Mar-24 The study is a randomized survey experiment examining how question wording affects public beliefs about nicotine causing cancer. It is not a therapeutic clinical trial in cancer patients, has no drug intervention, and does not report any time-to-event efficacy endpoint like overall survival or progression-free survival. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of oral mucositis management based on MASCC/ISOO guidelines in pediatric oncology patients: a randomized controlled trial. PMID 41863643 · Support Care Cancer · 2026-Mar-21 The study is a randomized trial in oncology with original results, but it is not a Phase III/IIIb or Phase II/III trial, does not have a primary time-to-event efficacy endpoint, and the intervention is a non-drug oral care protocol. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Efficacy of Ganciclovir Combined With Recombinant Human Interferon α-1b for Viral Encephalitis in Children]. PMID 42021910 · Sichuan Da Xue Xue Bao Yi Xue Ban · 2026-Mar-20 The study is a randomized trial in humans with a drug intervention (ganciclovir + interferon), but it investigates viral encephalitis, not a malignant neoplasm (oncology). The primary efficacy endpoints are symptom recovery time, clinical efficacy rate, EEG abnormalities, and biomarkers, none of which are time-to-event endpoints like OS or PFS. Therefore, it is excluded on both oncology and endpoint grounds. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer. PMID 41864769 · Eur Urol Oncol · 2026-Mar-20 The study is a randomized controlled trial for non-muscle-invasive bladder cancer reporting recurrence-free survival, which is a time-to-event endpoint. However, it does not meet the eligibility criteria because it is not a Phase III or Phase II/III trial (the phase is not specified as such in the abstract, and the deterministic review indicates it is not a phase 3 trial), and it does not involve a drug-containing intervention as defined for this cohort (the intervention is local chemoresection with mitomycin C, but this is a procedure-based/local therapy rather than a systemic drug intervention eligible for this specific cohort). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Reply to Roberto Contieri, Massimo Lazzeri, Sisto Perdonà, and Rodolfo Hurle's Letter to the Editor re: Kitamura, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008. PMID 41864759 · Eur Urol · 2026-Mar-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial. PMID 41863008 · Trials · 2026-Mar-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Kin KeeperSM Breast and Cervical Cancer Prevention: An Educational Intervention: A Community-Based Randomized Controlled Trial in Black, Latina, and Arab Women. PMID 41860672 · J Cancer Educ · 2026-Mar-20 The study is a randomized oncology trial in humans with original results, but it lacks a drug intervention and a time-to-event efficacy endpoint. It is an educational prevention study, not a Phase III drug efficacy trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Testing interventions to increase participation in the Australian National Bowel Cancer Screening Program among persistent never-screeners: study protocol for a randomised controlled trial. PMID 41857651 · Trials · 2026-Mar-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743. PMID 41734361 · J Clin Oncol · 2026-Mar-20 The record explicitly describes a randomized trial with a drug intervention in oncology (pleural mesothelioma) and reports primary time-to-event efficacy results (OS) with hazard ratios. Although the abstract does not explicitly state the phase, CheckMate 743 is a well-known Phase III trial, and the study's design (randomized, comparative, definitive efficacy endpoint) aligns with Phase III criteria. The report is a long-term follow-up of the original trial results. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 2 Figure · 5 Panel · risk visible |
| Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study. PMID 41628308 · J Clin Oncol · 2026-Mar-20 The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and is an original result report. However, it is excluded because its primary endpoint is not a time-to-event efficacy endpoint; it reports pharmacodynamic changes (Ki67, ER) rather than OS, PFS, or similar survival outcomes with associated Kaplan-Meier or HR data. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Induction Nivolumab Before Chemoradiation in High-Risk Human Papillomavirus-Driven Oropharynx Cancers: IMMUNEBOOST-HPV, a Multicenter Randomized Phase II Trial. PMID 41570275 · J Clin Oncol · 2026-Mar-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14). PMID 41862335 · Eur Urol Oncol · 2026-Mar-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |